CG Oncology CGON Institutional Ownership

Updated Oct 11, 2026

CG Oncology, Inc. (NASDAQ:CGON) was held by 227 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• Total holdings of CG Oncology shares rose 8.04% from Q1 2026, and the number of holders rose 42.77% from Q2 2025.
• Among the 227 holders of CG Oncology, 127 added to their positions, 72 reduced their stakes and 28 left their positions unchanged.
• Combined, institutional investors held 93.81Mn shares of CGON as of Q2 2026, up 6.98Mn from the prior quarter and up 19.95Mn from a year earlier.
• RTW Investments, LP was the top holder of CG Oncology as of June 30, 2026, with 8.51Mn shares.
• Among holders that already owned CG Oncology, the biggest buyers in Q2 2026 were Seven Fleet Capital Management LP (+1.81Mn shares), RTW Investments, LP (+1.53Mn shares), BlackRock, Inc. (+1.19Mn shares), SG Americas Securities, LLC (+842.83K shares) and State Street Corp (+790.54K shares).
• On the other side, among holders that kept a position in CG Oncology, the largest reductions in Q2 2026 came from Polar Capital Holdings PLC (-660.98K shares), Bank of America Corp (-464.45K shares), UBS Group AG (-334.28K shares), UBS Asset Management Americas (-303.16K shares) and Goldman Sachs Group Inc (-301.53K shares).
• Per Business Quant, the top 10 investors in CGON for the quarter ended June 30, 2026 were RTW Investments, LP (8.51Mn shares), T. Rowe Price Investment Management, Inc. (6.62Mn shares), Decheng Capital LLC (6.37Mn shares), BlackRock, Inc. (6.26Mn shares), Wellington Management Group LLP (5.32Mn shares), FMR LLC (4.16Mn shares), T. Rowe Price Associates Inc (3.81Mn shares), TCG Crossover Management, LLC (3.67Mn shares), Vanguard Portfolio Management LLC (3.47Mn shares) and State Street Corp (3.44Mn shares).